GREENWICH LIFESCIENCES, INC. Proceeds from (Repayments of) Related Party Debt
GREENWICH LIFESCIENCES, INC. (GLSI) reported Proceeds from (Repayments of) Related Party Debt of -$275.15 thousand for the 12-month period ending 2021-12-31, per its 10-K filed 2023-03-31.
Discontinued › Cash Flow › Financing Activities
us-gaap:ProceedsFromRepaymentsOfRelatedPartyDebt · last filed 2023-03-31
- GREENWICH LIFESCIENCES, INC. proceeds from (repayments of) related party debt for fiscal 2021 was -$275.15K.
| Period end | Proceeds from (Repayments of) Related Party Debt 12 month |
|---|---|
| 2021-12-31 | -$275.15K 10-K · filed 2023-03-31 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Mereo BioPharma Group plc (MREO) | $0.269B | -9.41 | |
| Akebia Therapeutics, Inc. (AKBA) | United States | $0.255B | -10.35 |
| Sagimet Biosciences Inc. (SGMT) | United States | $0.279B | |
| Upstream Bio, Inc. (UPB) | United States | $0.284B | -2.42 |
| Perspective Therapeutics, Inc. (CATX) | United States | $0.284B | -3.34 |
| Lyell Immunopharma, Inc. (LYEL) | United States | $0.248B | -1.32 |
| Contineum Therapeutics, Inc. (CTNM) | United States | $0.289B | -4.40 |
| Fulcrum Therapeutics, Inc. (FULC) | United States | $0.289B | -3.28 |
| Pyxis Oncology, Inc. (PYXS) | United States | $0.244B | |
| Entrada Therapeutics, Inc. (TRDA) | United States | $0.243B | -1.73 |